{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-123274","form_type":"8-K","ticker":"RNAZ","cik":"0001829635","company_name":"Transcode Therapeutics, Inc.","filed_at":"2023-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.824623+00:00","generated_at":"2026-06-07T18:52:21.286438+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"TransCode Therapeutics raises $1.21M in registered direct offering of 5M shares at $0.242/share","bullets":["Sold 5,000,000 shares of common stock at $0.242 per share, gross proceeds of $1.21 million.","Offering closed on December 4, 2023; H.C. Wainwright & Co. acted as exclusive placement agent.","Placement agent received warrants to purchase 300,000 shares at $0.3025 per share, exercisable for 5 years.","Net proceeds will fund clinical trials for lead candidate TTX-MC138 and for working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-123274","json":"https://secwatch.observer/filing/0001104659-23-123274.json","markdown":"https://secwatch.observer/filing/0001104659-23-123274.md","text":"https://secwatch.observer/filing/0001104659-23-123274.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829635/000110465923123274/0001104659-23-123274-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829635/000110465923123274/tm2332042d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T18:52:21.286438+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"10b6206742ef5e4dff29c19abf61589c36148f27","claim":"Transcode Therapeutics, Inc. entered into Securities Purchase Agreement with institutional investors named therein valued at $1.21 million (effective 2023-11-30).","evidence_excerpt":"On November 30, 2023, TransCode Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with institutional investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), an aggregate of 5,000,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at an offering price of $0.242 per share of Common Stock.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829635/000110465923123274/0001104659-23-123274-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"institutional investors named therein"},{"label":"Value","value":"$1.21 million"},{"label":"Effective","value":"2023-11-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}